Table 1.
Summary of the reported health benefits of rare sugar consumption (including only studies reporting significant results)§
| Observed effect of rare sugar | Human studies | Animal studies | ||||||
|---|---|---|---|---|---|---|---|---|
| Subjects with T2D, hyperglycaemia or obesity | Healthy subjects | Animal models of metabolic disease | Normal animals | |||||
| Reduced PEBG | PSI | Hayashi 2010(28) | PSI | Matsuo 2011(30) *,† | PSI | Hossain 2011(43), 2012(59), | SOR | Oku 2014(25) | 
| Noronha 2018(29) | Yamada 2018(31) *,† | Iwasaki 2018(51) | ||||||
| TAG | Kwak 2013(33) | Iida 2008(32) † | Pongkan 2020(64) | RSS | Shintani 2017(74) | |||
| RSS | Nakamura 2017(34) *,† | |||||||
| Improved long-term glycaemic control | TAG | Ensor 2014(38), 2015(40) | PSI | Baek 2010(58) | PSI | Iida 2013(66) ‡ | ||
| Do 2019(41) ‡ | ||||||||
| Han 2016(42) | ||||||||
| Hossain 2011(43). 2012(59). 2015(60) | ||||||||
| Reduced body weight | PSI | Han 2018(36) | RSS | Hayashi 2014(39) ‡ | PSI | Han 2016(42) ‡, 2020(44) ‡, 2020(45) ‡ | PSI | Huang 2018(76) † | 
| Donner 2010(37) | Baek 2010(58) | Nagata 2015(65) *,‡ | ||||||
| TAG | Ensor 2014(38) | Choi 2018(71) *,‡ | Yagi 2009(54) | |||||
| Chung 2012(72) | RSS | Iida 2013(66) ‡ | ||||||
| Do 2019(41) ‡ | Shintani 2017(74) | |||||||
| Hossain 2011(43), 2012(59) | ALL | Iga 2010(67) | ||||||
| Itoh 2015(46) | ||||||||
| Kim 2017(73) ‡ | ||||||||
| Ochiai 2013(62) | ||||||||
| Hossain 2015(60) | ||||||||
| TAG | Williams 2015(91) *,‡ | |||||||
| Reduced body fat | PSI | Han 2018(36) | RSS | Hayashi 2014(39) ‡ | PSI | Han 2020(44) ‡ | PSI | Chen 2017(48) *,‡,†, Chen 2019(49) *,‡ | 
| Choi 2018(71) *,‡ | ||||||||
| Hossain 2011(43) | ||||||||
| Itoh 2015(46) | ||||||||
| Kim 2017(73) ‡ | ||||||||
| Ochiai 2013(62) | ||||||||
| RSS | Ochiai 2017(63) *,‡ | |||||||
| Improved plasma lipid profile | TAG | Ensor 2015(40) | PSI | Han 2016(42) ‡, 2020(44) ‡, 2020(45) ‡ | PSI | Chen 2017(48) *,‡,†, Chen 2019(49) *,‡ | ||
| Baek 2010(58) | ||||||||
| Choi 2018(71) *,‡ | ||||||||
| Do 2019(41) ‡ | ||||||||
| Ochiai 2013(62) | ||||||||
| Hossain 2015(60) | ||||||||
| Kim 2017(73) ‡ | ||||||||
| Kanasaki 2019(61) *,‡ | ||||||||
| TAG | Williams 2015(91) *,‡ | |||||||
| Reduced hepatic lipid accumulation | PSI | Han 2016(42) ‡, 2020(44) ‡, 2020(45) ‡ | PSI | Chen 2019(49) *,‡ | ||||
| Do 2019(41) ‡ | ||||||||
| Hossain 2011(43) | ||||||||
| Itoh 2015(46) | ||||||||
| ALL | Yamamoto 2017(27) | |||||||
| Improved gut microbiome | PSI | Han 2020(44) ‡, 2020(45) ‡ | ||||||
| TAG | Son 2019(47) | |||||||
| Reduced inflammation | PSI | Han 2020(45) ‡ | ||||||
| TAG | Son 2019(47) | |||||||
| Improved oxidative status | PSI | Pratchayasakul 2020(50) † | PSI | Chen 2017(48) *,‡,†, Chen 2019(49) *,‡ | ||||
PEBG, postprandial elevation of blood glucose.
Indicates studies in which there was a possible energy deficit in the experimental group.
Indicates studies in which the rare sugar replaced another carbohydrate in the experimental diet.
Indicates studies available as abstracts only.
Studies reporting inconclusive or non-significant results have not been included.